EMErkin Isakovich Musabaev

Erkin Isakovich Musabaev

*This is an algorithmically generated author record based on publicly available information.

Erkin Isakovich Musabaev has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Molecular screening, regional infection patterns and phylogenetic characterization of spotted fever group Rickettsia in ticks from domestic animals in Uzbekistan

    by Adolat U Mirzaeva, Firuza D Akramova, Erkin I Musabaev, Djalaliddin A Azimov, Bakhtiyor R Kholmatov, Nargiza A Yarmukhamedova, Dilmurod A Kamolxodjaev, Shoira O Saidova, Ruziboy Q Shapaotov, Mukhammediyar Sh Toremuratov, et al.


  • Open Access

    Epidemiology of high-risk HPV in Uzbekistan among 44,000 women – genotypes, risk profiles and screening needs in Uzbekistan

    by Malokhat Palvannazirovna Oltieva, Dilfuza Abdullaevna Alieva, Sitorabonu Bahodir Kizi Abdusattorova, Iroda Pulatovna Sharipova, Jasur Ravshanovich Juraev, Tohirbek Shokir Ugli Shodiev, Erkin Isakovich Musabaev, Mirzarakhim Mirzakhakimovich Baynazarov, Khasanjon Kobiljon Ugli Odilov, Nurmuhammad Jaloliddin Ugli Jamoliddinov, et al.

    Cervical cancer imposes a substantial public health burden in Uzbekistan, yet comprehensive HPV epidemiological data are lacking. This study characterized high-risk HPV prevalence, genotype distribution, risk factors, and screening coverage in three key regions. We analyzed data from 44,497 women aged ≥ 20 years attending gynecological services in Tashkent, Andijan, and Samarkand (2021–2023). Liquid-based cytology and HPV DNA testing for 12 high-risk genotypes were performed. Sociodemographic, reproductive, behavioral, and clinical variables were collected via standardized questionnaires and examination. Multivariable logistic regression identified associated factors of high-risk HPV infection. High-risk HPV was detected in 3,779 women (8.5%), with regional prevalence of 9.2% in Andijan, 8.8% in Tashkent, and 6.5% in Samarkand. Mixed genotype infections comprised 52.8% of cases; HPV-16/18 accounted for 41.1%. Among HPV-positive women undergoing cytology (n = 2,275), 64.1% had negative findings, 14.7% LSIL, 8.4% ASC-US, 6.9% HSIL, 5.1% ASC-H, 0.5% atypical glandular cells, and 0.3% carcinoma. Independent predictors of HPV infection included younger age, single marital status, lower parity, abortion history, and hormonal contraception (all p < 0.05). Foamy vaginal discharge was a significant clinical predictor (adjusted OR 1.53; p < 0.01). Uzbekistan exhibits an intermediate high-risk HPV burden, dominated by vaccine-preventable genotypes, and low screening coverage. Targeted outreach to identified high-risk groups—by age, reproductive history, and clinical features—will optimize resource allocation. These data support accelerated progress toward WHO elimination targets in Uzbekistan. The online version contains supplementary material available at 10.1186/s12879-025-12096-7.


  • Open Access

    Expert Consensus on Improving Clinical Approaches to Managing Liver Diseases in Patients with Comorbidities

    by Igor Skrypnyk, Erkin Musabaev, Alexander Nersesov, Olena Baka, Olga Golubovska, Lola Daminova, Mamraim Dzhumabaev, Amangul Duisenova, Mirvasit Karimov, Nargiza Nurillaeva, et al.

    Non-alcoholic fatty liver disease affects up to 38% of the adult population worldwide, making it the most common chronic liver disease. It is a multisystem pathology, which is caused by systemic insulin resistance and related metabolic dysfunction, and lead to steatosis, steatohepatitis, fibrosis, cirrhosis and hepatocellular carcinoma, as well as to extrahepatic complications such as cardiovascular diseases, type 2 diabetes mellitus and chronic kidney disease. In 2023 the main international liver study associations have proposed to replace the term “non-alcoholic fatty liver disease” with “metabolic associated fatty liver disease” (MAFLD) to better reflect the metabolic origin of the disease. This change in terminology sparked greater scientific interest and a reassessment of clinical strategies. In March 2024, an Expert Forum on “Clinical Improvement of Approaches to Treating Liver Diseases in Comorbid Patients” brought together 16 key expert specialists of different specialities from Ukraine, Kazakhstan, Uzbekistan, Kyrgyzstan, Georgia, and Armenia. The forum focused on optimizing the treatment of MAFLD in patients with comorbid diseases. The consensus was adopted on the main recommendations: early diagnosis using modern imaging methods; lifestyle modification (diet and physical activity); pharmacotherapy; in some cases, bariatric surgery. Special attention was paid to the treatment of comorbidities, hepatogenic fatigue with ademetionine and the use of the Charlson index for survival prognosis. The document emphasizes the importance of a multidisciplinary approach, the need for further studies of pathogenesis and the development of targeted therapy. Implementation of these recommendations may improve the quality of life and long-term outcomes for patients with chronic liver disease. Conclusions. MAFLD is characterized by the accumulation of fat in the liver due to metabolic disorders. It is a common disease worldwide. Early diagnosis of the disease is vital because it can progress to severe and terminal conditions (steatohepatitis, cirrhosis, and liver cancer). Therapeutic strategies include: lifestyle changes, pharmacotherapy, and bariatric surgery. Further studies are needed to improve the understanding of the pathogenesis of MAFLD, identify biomarkers of this disease, and develop new therapeutic strategies.

  • Open Access

    Prevalence of high-risk human papillomavirus genotypes among women in Uzbekistan, 2021–2023

    by Iroda Pulatovna Sharipova, Erkin Isakovich Musabaev, Shakhlo Sobirovna Sadirova, Dildora Tolibjonovna Suyarkulova, Shavkat Ekrinovich Tashev, Shakhnoza Khayrullaevna Akhmedova, Nozimakhon Rakhmatullaxodjaevna Turabova, Saidkhon Makhmudkhonovich Sharapov, Rano Ibrahimovna Kasimova, Ravshan Abdullaevich Rakhimov, et al.

    Sharipova IP, et al. J Gynecol Oncol. 2024 Jun;36:e7. https://doi.org/10.3802/jgo.2025.36.e7


  • Treatment of the acute intestinal viral infections in children: results of the international multicenter doubleblind placebo-controlled randomized clinical trial

    by Children’s Scientific and Clinical Center for Infectious Diseases of the Federal Medical and Biological Agency, Yu.V. Lobzin, A.V. Gorelov, Central Research Institute of Epidemiology of the Federal Service on Customers' Rights Protection and Human Well-being Surveillance, D.V. Usenko, Е.V. Melekhina, V.A. Anokhin, Kazan State Medical University of the Ministry of Healthcare of the Russian Federation, O.V. Samodova, North State Medical University of the Ministry of Healthcare of the Russian Federation, et al.